3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Papillomavirus Infections
10
Uterine Cervical Neoplasms
6
Vulvar Neoplasms
3
Herpes Zoster
3
Condylomata Acuminata
3
Anus Neoplasms
3
Vaginal Neoplasms
2
Uterine Cervical Dysplasia
2
Whooping Cough
1
Tetanus
1
Persistent Infection
1
Neoplasms, Glandular and Epithelial
1
Neoplasms
1
Neoplasm Metastasis
1
Meningitis
1
High Grade Cervical Intraepithelial Neoplasia
1
Hematologic Neoplasms
1
Diphtheria
1
Interventions
Azacitidine
14
venetoclax
10
AP 1903 reagent
7
Rituximab
6
Dexamethasone
6
Itraconazole
5
Cytarabine
5
Bortezomib
5
fludarabine
4
fedratinib
4
belinostat
4
Nivolumab
4
Lenalidomide
4
Imatinib Mesylate
4
Daunorubicin
4
ARQ531
4
pomalidomide
3
ibrutinib
3
daratumumab
3
cc-486
3
angiotensin I (1-7)
3
Standard of Care
3
GSK2110183
3
Cyclophosphamide
3
zanubrutinib
2
tosedostat
2
tazemetostat
2
tanespimycin
2
talquetamab
2
tafasitamab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Neoplasms
×
Vaccines
×
Clear all
NCT01254630
2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3
Completed
5,305 enrolled
20 charts